Promising combo for tough hodgkin lymphoma cases shows strong response

NCT ID NCT03016871

First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 26 times

Summary

This study tested a combination of the immunotherapy drug nivolumab and chemotherapy (ICE) in 78 people with Hodgkin lymphoma that returned or didn't respond to initial treatment. The goal was to see if this approach could shrink tumors enough to allow a stem cell transplant. The treatment was tailored based on how well each person responded. Results showed many patients achieved complete remission, though side effects were monitored closely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, 98109, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.